title: [Interleukin-2 in the treatment of malignant melanoma. A case report].
abstract: Interleukin-2 is a lymphokine with documented antineoplastic influence, with not completely understood mechanism of action. The case of 46-years old patient with relapsed metastatic malignant melanoma treated with constant-infusion of rIL-2 is described. 9-month remission was achieved. During the course of treatment a lot of side effects including flu-like symptoms, hypotonia, anemia and thrombocytopenia, and also many biochemical disturbances were observed.
authors.affiliation: Zakładu Immunologii CSK WAM.
authors.forename: C
authors.initials: C
authors.lastname: Szczylik
authors.forename: J
authors.initials: J
authors.lastname: Knap
authors.forename: A
authors.initials: A
authors.lastname: Badowski
authors.forename: M Z
authors.initials: MZ
authors.lastname: Ratajczak
authors.forename: M
authors.initials: M
authors.lastname: Siekierzyński
mesh_terms: D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D007376:Interleukin-2
vernacular_title: Interleukin-2 (IL-2) w leczeniu czerniaka złośliwego. Opis przypadku.